These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21277882)

  • 1. A convenient synthesis of the side chain of loteprednol etabonate--an ocular soft corticosteroid from 20-oxopregnanes using metal-mediated halogenation as a key reaction.
    Chowdhury P; Borah JM; Goswami P; Das AM
    Steroids; 2011 Apr; 76(5):497-501. PubMed ID: 21277882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.
    Druzgala P; Hochhaus G; Bodor N
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):149-54. PubMed ID: 2004037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and structure elucidation of the major photodegradation products of loteprednol etabonate.
    Shirasaki Y; Inada K; Inoue J; Nakamura M
    Steroids; 2004 Jan; 69(1):23-34. PubMed ID: 14715374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques.
    Rachwal S; Pop E; Brewster ME
    Steroids; 1996 Sep; 61(9):524-30. PubMed ID: 8883218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD; Howes J; Crockett RS; Sherwood MB
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.
    Bodor N; Loftsson T; Wu WM
    Pharm Res; 1992 Oct; 9(10):1275-8. PubMed ID: 1448425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HPLC method to evaluate purity of a steroidal drug, loteprednol etabonate.
    Yasueda S; Higashiyama M; Shirasaki Y; Inada K; Ohtori A
    J Pharm Biomed Anal; 2004 Oct; 36(2):309-16. PubMed ID: 15496323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ; Djalilian AR; Sanderson JP
    Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
    Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
    Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
    Noble S; Goa KL
    BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate.
    Szelenyi I; Hermann R; Petzold U; Pahl A; Hochhaus G
    Pharmazie; 2004 May; 59(5):409-11. PubMed ID: 15212311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
    Hochhaus G; Chen LS; Ratka A; Druzgala P; Howes J; Bodor N; Derendorf H
    J Pharm Sci; 1992 Dec; 81(12):1210-5. PubMed ID: 1491342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
    Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
    Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
    Wu WM; Huang F; Lee Y; Buchwald P; Bodor N
    J Pharm Pharmacol; 2008 Mar; 60(3):291-7. PubMed ID: 18284808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loteprednol etabonate: a review of ophthalmic clinical studies.
    Howes JF
    Pharmazie; 2000 Mar; 55(3):178-83. PubMed ID: 10756536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of ocular inflammatory conditions with loteprednol etabonate.
    Pavesio CE; Decory HH
    Br J Ophthalmol; 2008 Apr; 92(4):455-9. PubMed ID: 18245274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit.
    Krug N; Hohlfeld JM; Geldmacher H; Larbig M; Heermann R; Lavallee N; Nguyen DT; Petzold U; Hermann R
    Allergy; 2005 Mar; 60(3):354-9. PubMed ID: 15679722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soft corticosteroids for local immunosuppression: exploring the possibility for the use of loteprednol etabonate for islet transplantation.
    Bocca N; Pileggi A; Molano RD; Marzorati S; Wu W; Bodor N; Ricordi C; Buchwald P
    Pharmazie; 2008 Mar; 63(3):226-32. PubMed ID: 18444512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.